Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Worenine is a bioactive isoquinoline alkaloid primarily isolated from the traditional Chinese medicinal herb *Coptis chinensis* (Coptidis Rhizoma). It has demonstrated significant anti-tumor activity across various cancers, including triple-negative breast cancer, non-small cell lung cancer, and colorectal cancer, often by reversing the Warburg effect and inhibiting HIF-1α signaling. Additionally, worenine acts as an inhibitor of T-lymphokine-activated killer cell-originated protein kinase (TOPK) and c-Jun N-terminal kinase 2 (JNK2), showing potential in treating inflammatory conditions like psoriasis and solar ultraviolet-induced sunburn. While it exhibits therapeutic potential, studies have also noted its potential for hepatotoxicity mediated by organic cation transporter 1 (OCT1) uptake and cytochrome P450-driven metabolic activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on worenine.